Google Search

Search

Already a Member ?

Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates, Pharmaceutical Drugs, Pharma Drug Ingredients Intermediates, Drug Intermediates, Speciality Chemicals, Raw Materials, Fine and Specialty Chemicals Intermediates, Pharmaceutical Bulk Drugs

Indian drugs and pharmaceutical industry has advanced perceptibly and is getting ready  for the new patent regime and  to withstand global competition, which is expected to be unleashed by new winds of liberalisation - a new era of liberalisation - much different from what was ushered in since the conclusion of the Uruguay Round and the establishment of the World Trade Organisation.

The industry has been expanding at annual rates ranging between 8 to 10% (against global growth rate of 6%).  According to a study  by McKinsey, Vision 2010, the domestic pharmaceutical industry could attain a size of  $25 billion (Rs 1200 billion) by 2010 by focusing on two areas: first, innovation-led research, development and new drug discoveries; and second, information technology-led remote sales and marketing.  The market for bulk drugs and formulations had increased from about Rs 103  billion in 1990-91 to an estimated Rs 435  billion at the end of 2003-04.  The prices of Indian essential drugs are among the lowest in the world. Apart from strides made by the industry in the last half-a-century, lower production cost due to reverse engineering and low R&D outlays has been a major factor in keeping the prices under check.

The global pharmaceutical industry is estimated at $ 300 billion, not all representing cross-border trade.  India's measly share of $ 1.5 billion in global trade represents an untapped potential. Under the regime of economic liberalisation underway since early 1990s, the drugs and pharmaceutical sector witnessed initiatives at fresh investment in the sector. Nearly 1735 investment proposals of the order of around Rs 166  billion were initiated. The foreign collaboration proposals approved numbered around 425 with a foreign direct investment  (FDI) component of over Rs 25 billion. The pharmaceuticals have figured high on the export front. In 2001-02,  the sector was  estimated to have registered a growth of 17.6% at around Rs 20.3 billion.

In the wake of economic liberalisation, many a  overseas players  returned or contemplated returning to India. These include Ivox Corp (USA),  Taro Pharmaceuticals (Israel) and Merck (USA). These are out either to set shop or looking for acquisitions in India. Hexal AG of Germany has established a liaison office in India. MILLIONCs like Rocha, Bayer, Aventis and Chiron are making India a regional hub for bulk drugs. 

The Export Import Bank of India (Exim Bank) had  doubled its corpus for the pharmaceutical industry to Rs 2 billion as a result of increased activity in the industry, especially in the external sector. The fund is used for the development and commercialisation of the new products and applications, significant improvement in the existing design of  products, setting up and expansion of pilot plants, research studies for obtaining regulatory approvals, cost of filing and managing international patent and R&D Centres.

It needs, however, to be recognised that the presence  of small scale manufacturers has resulted, on the one hand,  in a highly fragmented industry, and on the other, it has made it possible to supply a near 100,000 drugs including vitamins, antibiotics, antibacterials, cardio-vascular and other essential drugs. These account for nearly 37% of the market.  While each of about 80% of the manufacturers has annual sales below a billion rupees, top ten companies are known to control over 30% of the market. At present there are more than 20,000 players in the country.

The major players are: Alembic Chem, Aurobindo Pharma, Cipla, Dr. Reddy's, FDC, IPCA Labs, Jagsonpal Pharma, J.B. Chemicals, Kopran, Lupin Labs, Lyka Labs, Morepan Labs, Nicholas Piramal, Ranbaxy Labs, Sun Pharma, Themis Medicare, GlaxoSmithkline, Astrazeneca, Aventis, E-Merck, Torrent Pharma, TTK Healthcare, Unichem Labs,  Wockhardt  and  Zandu Pharma.  Until recently, only a few of the Indian companies had gone into any serious R&D activity. Much of the effort was directed to affordable analogue research. The R&D level in the country is low with even well-placed pharma companies spending less than 2% of turnover on R&D. MILLIONCs are known to contribute as much as 10% or more of their turnover to R&D.  While India is very strong in process chemistry, biology and applied bio-chemistry, initiatives at all levels - government, academia, private sector - involving heavy financial outlays, are called for.

Ayurveda continues to remain a preferred system of medicine for a vast segment of population in the country. The country has over 400,000 registered practitioners of the Indian system of medicine. Around 170 institutes properly affiliated to various universities impart under- or post-graduate courses each year. These institutes churn out some 5,500 fresh practitioners. The practitioners are supported by 12,000 dispensaries and 2,100 beds available for ayurveda treatment countrywide. The emerging biotechnology sector has already taken by storm and is offering sops to states to make these as the thriving ground for the highly potential segment in medicare.

We can provide you detailed project reports on the following topics. Please select the projects of your interests.

Each detailed project reports cover all the aspects of business, from analysing the market, confirming availability of various necessities such as plant & machinery, raw materials to forecasting the financial requirements. The scope of the report includes assessing market potential, negotiating with collaborators, investment decision making, corporate diversification planning etc. in a very planned manner by formulating detailed manufacturing techniques and forecasting financial aspects by estimating the cost of raw material, formulating the cash flow statement, projecting the balance sheet etc.

We also offer self-contained Pre-Investment and Pre-Feasibility Studies, Market Surveys and Studies, Preparation of Techno-Economic Feasibility Reports, Identification and Selection of Plant and Machinery, Manufacturing Process and or Equipment required, General Guidance, Technical and Commercial Counseling for setting up new industrial projects on the following topics.

Many of the engineers, project consultant & industrial consultancy firms in India and worldwide use our project reports as one of the input in doing their analysis.

We can modify the project capacity and project cost as per your requirement.
We can also prepare project report on any subject as per your requirement.

Page 12 of 21 | Total 201 projects in this category
« Previous   Page 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 .... 20 21   Next »

Add multiple items to inquiry
Select the items and then press Add to inquiry button

Select all | Clear all Sort by

L-LYSINE FROM MICROBIAL FERMENTATION - Manufacturing Plant, Detailed Project Report, Profile, Business Plan, Industry Trends, Market Research, Survey, Manufacturing Process, Machinery, Raw Materials, Feasibility Study, Investment Opportunities

L-Lysine is an ?-amino acid with the chemical formula HO2CCH(NH2)(CH2)4NH2. It is an essential amino acid for humans. Lysine's codons are AAA and AAG. Lysine is a base, as are arginine and histidine. The ?-amino group often participates in hydrogen bonding and as a general base in catalysis. (The ?-amino group (NH3+) is attached to the fifth carbon beginning from the ?-carbon, which is attached to the carboxyl (C=OOH) group. Common posttranslational modifications include methylation of the ?-amino group, giving methyl-, dimethyl-, and trimethyllysine. The latter occurs in calmodulin. Other posttranslational modifications at lysine residues include acetylation and ubiquitination. Collagen contains hydroxylysine, which is derived from lysine by lysyl hydroxylase. O-Glycosylation of hydroxylysine residues in the endoplasmic reticulum or Golgi apparatus is used to mark certain proteins for secretion from the cell. Lysine is one of the essential amino acids not synthesized biologically in the body. Children and growing animals have a high requirement of lysine, since it is needed for bone formation. Lysine is generally recognized as the most deficient amino acid in the food supply of both man and domestic meat producing animals. Since animal feed, such as grain and defatted oil seeds contain only small quantities of lysine, poultry, cattle and other live stocks are unable to synthesize this amino acid. So it must be added to these feed stuff to provide adequate diet. The excretion of small amount of alanine, glutamic acid, aspartic acid and histidine in a culture of E. coli. addition of ammonium salt in excess of that required for growth resulted in increased amino acid production. The principles of the fermentative method quickly gained acceptance, and systematic work soon began on the production of other amino acids. This marked the birth of the amino acid fermentation industry.The possible utilization of wild strain revealed that many microorganisms, such as bacteria, yeast, filamentous fungi and action mycetes, accumulated amino acids in culture containing a supplementary source of nitrogen. The biosynthetic pathways of most amino acids are now well moved to metabolic control and its break down, including the genus and species specificity of the phenomenon. Protein production by microorganisms rich in essential amino acids are source both as a food supplement and as a source of amino acid. Fifteen amino acids were found in cell hydrolyzate, of which arginine and L-lysine is the most abundant. Most natural strains cannot produce industrially significant amounts of L-lysine in the culture broth due to various metabolic regulation mechanisms. Alteration of these mechanism can lead to L-lysine accumulation. USES & APPLICATION Lysine production for animal feed is a major global industry, reached in 2009 almost 700,000 tonnes for a market value of over €1.22 billion. Lysine is an important additive to animal feed because it is a limiting amino acid when optimizing the growth of certain animals such as pigs and chickens for the production of meat. Lysine supplementation allows for the use of lower-cost plant protein (maize, for instance, rather than soy) while maintaining high growth rates, and limiting the pollution from nitrogen excretion. In turn, however, phosphate pollution is a major environmental cost when corn is used as feed for poultry and swine. Lysine is industrially produced by microbial fermentation, from a base mainly of sugar. Genetic engineering research is actively pursuing bacterial strains to improve the efficiency of production and allow lysine to be made from other substrates. The requirements of amino acids in animals are well defined in various sets of recommendations such as those of NRC (National Research Council), USA, etc. Requirements vary depending on the species and age of animals. Amino acids should be supplied either in the form of protein or crystalline amino acids in feed to meet requirements. By comparing requirements and the actual amino acids present in feed, the order of ‘limiting amino acids’ can be estimated. The orders of limiting amino acids in pig and broiler feeds, composed of corn (or wheat) and soybean meal. Crystalline amino acids should be added to feed in the order of limiting amino acids when the protein content of the feed is reduced, which is the reason why DL-Methionine and L-Lysine HCl were initially introduced to feed. Now, with a more economic supply of L-Threonine and L-Tryptophan available, use of amino acids has entered a new era, in which the use of second and third limiting amino acids is taking off. For example, in the past two to three years, the annual growth rate of L-Threonine usage has been above 20 percent. Since the protein level required by livestock is reduced further with the introduction of second and third limiting amino acids, use of the first limiting amino acid will also be expanded. MARKET SURVEY It can be said that the use of L-Lysine in animal feed in India is largely in the introductory stage at present. The demand is bound to go up, in view of the compulsive need to optimise the quality of the animal feed by the producers to stay ahead in the competitive market. The Indian demand for L-Lysine is estimated to be around 1000 tonnes per annum. Estimated growth rate in demand: 9 to 10% per annum. The global demand for L-Lysine Hydrochloride is around 5,00,000 tonnes per annum with the projected growth rate in demand of around 8.0%. Considering the fact that around 25,000 tonnes of additional capacity has to be created for L-Lysine Mono-hydrochloride to meet the global demand every year, it should be possible for the Indian project to take substantial share in the export market. This would be so, in view of the fact that the Molasses based L-Lysine project in India would be globally competitive from the point of view of the cost factors. The important aspects of the L-Lysine is that the product is based on cane molasses, which is adequately available in the country.
Plant capacity: 17 MT/DayPlant & machinery: Rs 328 Lakhs
Working capital: -T.C.I: Cost of Project: Rs 910 Lakhs
Return: 24.64%Break even: 52.18%
Add to Inquiry Add to Inquiry Basket

FRUCTOSE SYRUP FROM BROKEN RICE (HFS 90%)- Manufacturing Plant, Detailed Project Report, Profile, Business Plan, Industry Trends, Market Research, Survey, Manufacturing Process, Machinery, Raw Materials, Feasibility Study, Investment Opportunities

Glucose syrup is a popular substitute for sugar. It is more commonly referred to as corn syrup because its main ingredient is usually cornstarch. From a strictly chemical perspective, glucose syrup is the proper term for any liquid starch consisting of carbohydrates. In addition to cornstarch, it can be made from any form of starch, including wheat, rice or potatoes. Because of its successful and easy bonding with dry or solid substances, this syrup is the preferred sweetener for candy, chewing gum, jams, jellies and canned fruit. The main benefit of this syrup over regular granulated sugar is its non-crystallizing properties. It is also praised for its preservative qualities. Makers of chocolate, ice cream and bakery products also prefer this syrup to sugar. Ice cream makers appreciate the anti-melting feature it adds to the frozen treat. Cream and fruit fillings in bakery products get a lot of their fluffiness and bulk from this type of syrup. Non-sweet foods and drinks also benefit from glucose syrup. The syrup also aids in fermentation and brewing processes utilized in beer and alcohol production. The high carbohydrate content preferred in processed baby foods is provided by the addition of this sugar substitute as well. Products not normally associated with sugar or sweeteners, such as pharmaceuticals, also contain this versatile syrup. It is used to flavor cough syrups and to make the coatings on vitamin and medicine tablets. Chewing tobacco is flavored with glucose syrup as well, which makes it appealing to the palate. The tobacco used in cigarette production is treated with this syrup solution to smooth out the taste of the tobacco. Both products also remain fresher longer due to the addition of this sweet additive. Non-consumables, such as leather, benefit from glucose syrup used in the tanning process. Dipping leather in glucose syrup gives it an appealing, glossy shine and makes the grain look fine. The syrup also makes the leather more pliable. When incorporated into oil extraction procedures, glucose syrup aids in the thickening process and adds gumming properties. Along those same lines, it stabilizes glues and adhesives and aids in keeping concrete from hardening too quickly. High fructose syrup is one kind of colorless or light yellow, transparent ropy liquid. It is gentle and sweet with special odour of fructose with neither any abnormal taste nor impurities. It has two types: one is 42%, the other is 55%. Fructose is processed from hydrolyzed rice starch and contains fructose a simple sugar carbohydrate, just like sucrose. It is about 95% sweeter than sucrose, less expensive than sugar, and mixed well in many foods. The content of fructose is more than 42% of total carbohydrates. USES & APPLICATION For human health, it can stimulate the metabolism of blood alcohol, which is helpful to prevent the damage caused by the excessive blood alcohol. A patient with 500ml fructose (40%) injection mainlined will gain good recovery. Fructose is one of natural carbohydrates that consist in fruits as well as in honey. With high sweet it can substitute for sucrose, which has some advantages: Fructose, also called "fruit sugar", is another important hexose found in many fruits and vegetables. Fructose satisfies the "sweet tooth", tasting twice as sweet as sucrose so it can be used in lower amounts. With good sweet sense and taste it is favorable for the use in carbonated drinks, beverages. It has already be used in some big drinks such as Coca Cola. Pepsi-Cola etc. It can improve textures and enhance colors without masking natural flavors, as in canned fruits and vegetables. So, it has already been a king of good sweetener in the beverage industry. It maintains moisture so cakes or breads keep soft, fresh without going stale and longer shelf life. It can depress freezing to prevent crystal formation in ice cream and other frozen desserts and keep products soft and delicious. Fructose is widely used in beverages, carbonated drinks, fruit drinks, breads, cakes, tinned fruits, jams, succades, dairy foods etc. MARKET SURVEY Indian tops the list sugar producing countries. The status of sugar industries in India, indicates that the existing sugar mills are a typical mix of old and new plants. Per capita consumption of sugar and other products like Gur and Khandsari is going up and is expected to increase from 12.3 and 12.5 kg to 17.0 kg and 16.0 kg respectively by the end of this century. Studies on the raw material situation for the last 13 years reveal, that cane production has stagnated at about 60 tons per hectare with less than 1% increase per year from 1977-78 to 1989-90. Any scope of enhanced production of sugar-cane must come mainly from the development of high yielding varieties and improved farm practices. The limitation of traditional sources for meeting the ever increasing demand of sweeteners must be recognized. Therefore, manufacture of sweeteners based on starchy materials offers an attractive source to fill up the demand-supply gap of sugar as suggested by experts. The Indian scene of HFCS industry is at a nascent stage. One or two units engaged in this field are either in the establishment stage or had stopped producing HFCS due its high cost of production and poor demand in the consumer sector. The production and consumption of this particular product is not only limited due to its high cost, but also due to a general non-awareness about HFCS in the society. So, promotion of HFCS industry also demands an intensive campaign, highlighting the important advantages of HFCS, especially its rapid metabolism process in the human body and independence of insulin. The know-how for the manufacture of maize starch and its subsequent conversion to liquid glucose, meltodextrines, dextrose and sorbitol is indigenously available. HFCS is finding an increased use in soft drinks manufactured in the advanced countries. 50% to complete replacement of sugar with HFCS has been permitted in the U.S.A. Soft drink manufacturers in the country may also be persuaded to opt initially for at least 15-20% replacement. Gradually, other industries like bakery, processed foods, ice-creams etc., should also consider sugar replacement by HFCS.
Plant capacity: 30 MT/DayPlant & machinery: Rs. 343 Lakhs
Working capital: -T.C.I: Cost of Project: Rs. 1525 Lakhs
Return: 24.28%Break even: 55.59%
Add to Inquiry Add to Inquiry Basket

PHARMACEUTICAL PELLETS AND GRANULES - Manufacturing Plant, Detailed Project Report, Profile, Business Plan, Industry Trends, Market Research, Survey, Manufacturing Process, Machinery, Raw Materials, Feasibility Study, Investment Opportunities

The word “Pellet” has been used to describe a variety of systematically produced, geometrically defined agglomerates obtained from diverse starting materials utilizing different processing conditions. Pellets range in size, typically, between 0.5 – 1.5 mm, though other sizes could be prepared. Pellets are for pharmaceutical purposes and are produced primarily for the purpose of oral controlled-release dosage forms having gastro resistant or sustained-release properties or the capability of site-specific drug delivery. For such purposes, coated pellets are administered in the form of hard gelatin capsules or disintegrating tablets that quickly liberate their contents of pellets in the stomach. As drug-delivery systems become more sophisticated, the role of pellets in the design and development of dosage forms is increasing. Formulation of drugs in multiple-unit dosage forms, such as coated pellets filled in capsules or compressed into tablets, offers flexibility as to target-release properties. The safety and efficacy of the formulation is higher than that of other dosage forms. Solid dosage formulation and design usually involves a serious of compromises, since producing the desired properties frequently involves competing objectives. The correct selection and balance of excipients materials and processes in a solid dosage formulation, to achieve the desired response is not in practice easy to achieve. Pellets are of a great interest to the pharmaceutical industry for a variety of reasons. Palletized products not only offer flexibility in dosage form design and development, but are also utilized to improve the safety and efficiency of bioactive agents. Pellets range in size, between 0.5 to 1.5. USES & APPLICATION Pellets/ granules may have varied applications in varied industries. It just requires an innovative bend to use it to derive maximum profitability. The smooth surface & the uniform size of the pellets allow uniform coating not only for each pellet but also from batch to batch. Highlighted below are some of the few instances where smooth surfaced uniform pellets are being successfully used: Improved appearance of the products. Coating of pellets can be done with different drugs to enable a controlled release rate. In case of immediate Release Products larger surface area of pellets enables better distribution. Chemically incompatible products can be formed into pellets & delivered in a single dose by encapsulating them. In the chemical industries it is used to avoid powder dusting. Varied applications are possible in the pellet form. Eg: sustained release. Pellets ensure improved flow properties, and flexibility in formulation development and manufacture. The coating material may be colored with a dye material so that the beads of different coating thickness will be darker in color and distinguishable from those having fewer coats. The beads or granules of different thickness of coatings are blended in the desired proportions to give the desired effect. The thickness of the coat on the pellets dictates the rate at which the drug/ contents are released from the coated particles. A smooth surface of the pellets & uniform coating thickness for each pellet. By selecting the proper formulation, processing conditions and processing equipment it is possible to attain smooth surfaced & uniform pellets. The most common advantages of pelletization are: Improved appearance of the product and the core is pharmaceutically elegant. Pelletization offers flexibility in dosage form design and development, Pellets are less susceptible to dose dumping, It reduces localized concentration of irritative drugs, It improves safety and efficacy of a drug, Pellets offer reduced variation in gastric emptying rate and transit time, Pellets disperse freely in G.I.T. and invariably maximize drug absorption and also reduce peak plasma fluctuation, Pellets ensure improved flow properties in formulation development. MARKET SURVEY The Indian pharmaceutical industry is the fourth largest in the world in terms of volume of output and thirteenth in domestic demand. However, the Indian industry, valued at USD 17 bn in represented just over 1% of the global pharmaceutical industry (USD 1700 bn) in value terms. The domestic market is estimated at Rs 680 bn. According to the Federation of Indian Chambers of Commerce and Industry (FICCI), another apex industry association, there are some 6,000 firms engaged in the sector. In terms of revenue gene-ration, there are 100 big companies (including subsidiaries of MNCs) each with sales of at least USD 650,000, 200 medium size companies with sales ranging between USD 210,400 and USD 650,000; and 5700 small companies with sales of less than USD 210,400. Because many of these companies focus on producing similar generic or same drugs, the industry is characterized by fierce competition and high volumes, razor-thin profit margins, overcapacity, and declining prices. The growth has been driven by many factors, such as legislative reforms, growth in contract manufacturing and outsourcing, value added foreign acquisitions and joint ventures and India's acumen and expertise in reverse engineering of patented drug molecules. India has, in the meantime, been trying to comply with the World Trade Organization's Trade Related Intellectual Property Agreement (TRIPs) obligations. India is now among the top five pharmaceutical emerging markets. The Indian pharma industry has been growing at a compounded annual growth rate (CAGR) of more than 15 per cent over the last five years and has significant growth opportunities. The Indian pharmaceutical sector is expected to grow five-fold to reach Rs 5 lakh crore (US$ 91.45 billion) by 2020, as per Dr A J V Prasad, Joint Secretary, Department of Pharmaceuticals (DoP). The industry, particularly, has been the front runner in a wide range of specialties involving complex drugs' manufacture, development, and technology. With the advantage of being a highly organized sector, the number of pharmaceutical companies are increasing their operations in India. PRESENT MANUFACTURERS Abbott India Ltd. Anglo-French Drugs & Inds. Ltd. Biological E. Ltd. Boehringer Mannheim India Ltd. Cadila Laboratories Pvt. Ltd. Cadila Pharmaceuticals Ltd. Chemcel Biotech Ltd. Cosme Farma Laboratories Ltd. Fermenta Biotech Ltd. H P M Industries Ltd. Indian Drugs & Pharmaceuticals Ltd. Inventia Healthcare Pvt. Ltd. M S T C Ltd. Mayo (India) Ltd. Neo Corp Intl. Ltd. Northern Minerals Ltd. Pharmacia Healthcare Ltd. Rhyme Organics & Chemicals Ltd. Sandoz (India) Ltd. Sanofi India Ltd. Sarvodaya Labs Ltd. Shiv Herbal Research Laboratory Ltd. Sidmak Laboratories (India) Pvt. Ltd. Smith Stanistreet Pharmaceuticals Ltd. Stanpacks (India) Ltd. T T K Healthcare Ltd. Varun Polymol Organics Ltd. Virgo Polymers (India) Ltd. Wallace Pharmaceuticals Ltd.
Plant capacity: 600 Kgs/DayPlant & machinery: Rs. 208 Lakhs
Working capital: -T.C.I: Cost of Project: Rs. 547 Lakhs
Return: 26.86%Break even: 63.39%
Add to Inquiry Add to Inquiry Basket

PHARMACEUTICAL UNIT (Automatic Plant of Tablet and Capsule) - Manufacturing Plant, Detailed Project Report, Profile, Business Plan, Industry Trends, Market Research, Survey, Manufacturing Process, Machinery, Raw Materials, Feasibility Study

The Indian pharmaceutical sector has come a long way, being almost non-existent before 1970 to a prominent provider of healthcare products, meeting almost 95 per cent of the country's pharmaceuticals needs. The Industry today is in the front rank of India’s science-based industries with wide ranging capabilities in the complex field of drug manufacture and technology. It ranks very high in the third world, in terms of technology, quality and range of medicines manufactured. From simple headache pills to sophisticated antibiotics and complex cardiac compounds, almost every type of medicine is now made indigenously. Indian Pharma Industry is playing a key role in promoting and sustaining development in the vital field of medicines, besides this it boasts of quality producers and many units approved by regulatory authorities in USA and UK. International companies associated with this sector have stimulated, assisted and spearheaded this dynamic development in the past 53 years and helped to put India on the pharmaceutical map of the world. The Indian Pharmaceutical sector is highly fragmented with more than 20,000 registered units. It has expanded drastically in the last two decades. The leading 250 pharmaceutical companies control 70% of the market, with market leader holding nearly 7% of the market share. It is an extremely fragmented market with severe price competition and government price control. The pharmaceutical industry in India meets around 70% of the country's demand for bulk drugs, drug intermediates, pharmaceutical formulations, chemicals, tablets, capsules, orals and injectables. There are about 250 large units and about 8000 Small Scale Units, which form the core of the pharmaceutical industry in India (including 5 Central Public Sector Units). These units produce the complete range of pharmaceutical formulations, i.e., medicines ready for consumption by patients and about 350 bulk drugs, i.e., chemicals having therapeutic value and used for production of pharmaceutical formulations. Technologically strong and totally self-reliant, the pharmaceutical industry in India has low costs of production, low R&D costs, innovative scientific manpower, strength of national laboratories and an increasing balance of trade. The Pharmaceutical Industry, with its rich scientific talents and research capabilities, supported by Intellectual Property Protection regime is well set to take on the international market. Market Survey The Indian pharmaceutical industry is the fourth largest in the world in terms of volume of output and thirteenth in domestic demand. However, the Indian industry, valued at USD 17 bn in represented just over 1% of the global pharmaceutical industry in value terms. The domestic market is estimated at Rs 680 bn. According to a study by McKinsey, Vision 2010, the domestic pharmaceutical industry could attain a size of USD 25 bn (Rs 1200 bn) by 2010 by focusing on two areas: first, innovation-led research, development and new drug discoveries; and second, information technology-led remote sales and marketing. Incidentally, according to another report by Associated Chamber of Commerce (ASSOCHAM) in India, the market is estimated to grow to more modest level of USD 9.5 bn in 2010). India has the world's third largest active pharmaceutical ingredients (API) for the industry valued at a little less than USD 2 bn. Top 5 API producers account for approximately 6.5 %. The leading APIs are anti-infective, gastrointestinal, cardiovascular and respiratory drugs. However, India's pharmaceutical industry might witness some decline in the number of smaller companies that either leave the market or are acquired by larger Indian or foreign companies. Since 2000, a number of smaller Indian pharmaceutical companies have, in fact, been acquired by larger companies. These cases include, among the more notable ones, Wockhardt's acquisition of Merind and Tata Pharma; Ranbaxy's purchase of Crosland; Nicholas Piramal's acquisition of Roche etc. The Indian firms produce nearly 60,000 generic brands in 60 therapeutic categories and between 350 and 400 bulk drugs. India's drug market consists mainly of second and third generation drugs no longer subject to patent protection in the developed world. Although India is the world's leading producer of generic drugs, its annual per capita consumption of pharmaceuticals has been among the lowest placed approximately at USD 4.50 per person as compared to USD 820 in the United States and USD 13 in China. The bulk drugs segment continues to be the highest revenue generating segment for the Indian pharma industry. It accounts for production worth Rs 120 bn and contributes about 36% of the total pharma exports. India produces 400 bulk drugs through its 1,300 licensed bulk drug units that cater to most of the domestic bulk drug requirements. The key categories driving growth are the traditionally largest segment - anti-infective and gastro-intestinal, drugs, which expanded by 22% and 19% respectively. Fast sales growth is also visible in categories like respiratory (18%), cardiac (14%), neurology (20%) and anti-diabetic (19%). Anti-TB is the only category that has seen a decline in value and volume terms. The number of product launches exceeds 2,000 annually. Both MNC and Indian companies are implementing strategies which will help them to benefit from and cope with the developing patent regime. Global pharma companies are increasingly exploring low cost option to outsource research and manufacturing, because of emerging slow-down in patented drug sales and high cost of R&D. Indian pharmaceutical companies are in various stages of new drug discoveries. They have been scouting for global partners to help them in their goal. However, companies like Dr Reddy's Laboratories, Wockhardt’s, Glen mark Pharmaceuticals, Ranbaxy Laboratories, Orchid Chemicals and Lupin need financial and technical support from foreign pharmaceutical players to take their new drugs to the global market. Dr. Reddy's Laboratory (DRL) recently announced the beginning of Phase III clinical trials of its anti-diabetic drug Balagliatzone. Co-developed with Danish firm Rheoscience, the successful completion of the trial could give India its first intellectual property from the pharma sector. India has the highest number of (US Food and Drug Administration) USFDA approved manufacturing facilities outside the US and this puts India in good position to export to regulated markets. The major players in the country are: Aanjaneya Lifecare Ltd. Aashi Industries Ltd. Abbott India Ltd. Advik Laboratories Ltd. Aesculapius Remedies Ltd. Ajanta Pharma Ltd. Albert David Ltd. Alkem Laboratories Ltd. Alpa Laboratories Ltd. Ambalal Sarabhai Enterprises Ltd. Amee Cosmo Pharma Ltd. American Remedies Ltd. Amstrin Healthcare Ltd. Anan Drug & Chem Ltd. Andre Laboratories Ltd. Anglo-French Drugs & Inds. Ltd. Ankur Drugs & Pharma Ltd. Anmol Drugs & Pharmaceuticals Ltd. Anuh Pharma Ltd. Apex Laboratories Ltd. Apple Laboratories Ltd. Armour Chemicals Ltd. Arvind Remedies Ltd. Astrazeneca Pharma India Ltd. Astron Drugs & Inds. Ltd. Aurobindo Pharma Ltd. Aventis Pharma Ltd. B D H Industries Ltd. Bafna Pharmaceuticals Ltd. Bal Pharma Ltd. Basav Chem Ltd. Bassein Drugs Ltd. Beem Healthcare Ltd. Bengal Immunity Ltd. Beryl Drugs Ltd. Bharat Parenterals Ltd. Bharat Serums & Vaccines Ltd. Biddle Sawyer Ltd. Bio-Ethicals Pharma Ltd. Biocon Biopharmaceuticals Pvt. Ltd. Biocon Ltd. Biofil Chemicals & Pharmaceuticals Ltd. Biological E. Ltd. Blue Cross Laboratories Ltd. Boehringer Mannheim India Ltd. Brabourne Enterprises Ltd. Bravo Healthcare Ltd. Brawn Biotech Ltd. Burroughs Wellcome (India) Ltd. Cadila Healthcare Ltd. Cadila Laboratories Pvt. Ltd. Cadila Pharmaceuticals Ltd. Caplin Point Laboratories Ltd. Caryl Laboratories Ltd. Casil Industries Ltd. Celestial Biolabs Ltd. Centaur Pharmaceuticals Pvt. Ltd. Cepham Organics Ltd. Cepham Pharmaceuticals Ltd. Chemech Laboratories Ltd. Chemosyn Ltd. Ciba Ckd Biochem Ltd. Claris Lifesciences Ltd. Colinz Laboratories Ltd. Combat Drugs Ltd. Concept Pharmaceuticals Ltd. Concord Biotech Ltd. Concord Drugs Ltd. Coral Laboratories Ltd. Core Laboratories Ltd. Cosme Farma Laboratories Ltd. Cosme Pharma Ltd. Creative Health Care Pvt. Ltd. Croslands Research Laboratories Ltd. Croydon Chemical Works Ltd. Curewell (India) Ltd. Damania Pharma Ltd. Deepharma Laboratories Ltd. Deepharma Ltd. Dey'S Medical Stores Mfg. Ltd. Dishman Pharmaceuticals & Chemicals Ltd. Dolphin Laboratories Ltd. Dr. Reddy'S Laboratories Ltd. Druid Pharma Ltd. Dujohn Laboratories Ltd. Dumex Ltd. Eaco Labs Ltd. Earnest Healthcare Ltd. East India Pharmaceutical Works Ltd. Ebers Pharmaceuticals Ltd. Elder Health Care Ltd. Elder Pharmaceuticals Ltd. Elder Projects Ltd. Elvina Pharmaceuticals Ltd. Emaai Pharma Ltd. Emcure Pharmaceuticals Ltd. Endo Labs Ltd. Entod Pharmaceuticals Ltd. Esskay Pharmaceuticals Ltd. Ethnor Ltd. Eupharma Laboratories Ltd. Everest Organics Ltd. Evid & Co. Chemicals Ltd. F D C Ltd. Fine Drugs & Chemicals Ltd. Flamingo Pharmaceuticals Ltd. Fredun Pharmaceuticals Ltd. Fresenius Kabi Oncology Ltd. Fulford (India) Ltd. Geno Pharmaceuticals Ltd. Gentech Laboratories Ltd. Geoffrey Manners & Co. Ltd. German Remedies Ltd. Glaxosmithkline Pharmaceuticals Ltd. Glen mark Exports Ltd. Glen mark Generics Ltd. Glen mark Laboratories Ltd. Glen mark Pharmaceuticals Ltd. Global Remedies Ltd. Goa Antibiotics & Pharmaceuticals Ltd. Group Pharmaceuticals Ltd. Guardian Health Care Ltd. Gufic Biosciences Ltd. Gujarat Inject Ltd. Gujarat Terce Laboratories Ltd. Gujarat Themis Biosyn Ltd. H O D Laboratories Ltd. Hab Pharmaceuticals & Research Ltd. Haffkine Ajintha Pharmaceuticals Ltd. Hallmark Healthcare Ltd. Harleystreet Pharmaceuticals Ltd. Health Care Ltd. Hexone Pharmaceuticals Ltd. Hindustan Max-Gb Ltd. Hub Pharmaceuticals Pvt. Ltd. I D P L (Tamil Nadu) Ltd. Icon Biopharma & Healthcare Ltd. Icpa Health Products Ltd. Idma Laboratories Ltd. Ind-Swift Laboratories Ltd. Ind-Swift Ltd. India Infusion Ltd. Indian Drugs & Pharmaceuticals Ltd. Indoco Healthcare Ltd. Indoco Remedies Ltd. Indon Healthcare Ltd. Innotech Pharma Ltd. Intas Pharmaceuticals Ltd. Intercare Limited Intercare Ltd. International Drug Co. Ltd. Inventia Healthcare Pvt. Ltd. Inwinex Pharmaceuticals Ltd. Ipca Laboratories Ltd. Ivee Injectaa Ltd. J B Chemicals & Pharmaceuticals Ltd. J K Pharmachem Ltd. Jagsonpal Exports India Pvt. Ltd. Jagsonpal Pharmaceuticals Ltd. Jenburkt Pharmaceuticals Ltd. Jilichem Laboratories (India) Ltd. John Wyeth (India) Ltd. Johnson & Johnson Ltd. Kabra Drugs Ltd. Kappac Pharma Ltd. Karnataka Antibiotics & Pharmaceuticals Ltd. Kee Pharma Ltd. Kilitch Drugs (India) Ltd. Konkan Capsules Ltd. Krebs Biochemicals & Inds. Ltd. Labinduss Ltd. Lekar Healthcare Ltd. Lekar Pharma Ltd. Lincoln Pharmaceuticals Ltd. Liva Healthcare Ltd. Lordvin Labs Ltd. Lupin Laboratories Ltd. Lupin Ltd. Lyka B D R International Ltd. Lyka Labs Ltd. Lympha Laboratories Ltd. M J Pharmaceuticals Ltd. Macleods Pharmaceuticals Ltd. Maharashtra Antibiotics & Pharmaceuticals Ltd. Makers Laboratories Ltd. Maneesh Pharmaceuticals Ltd. Manipur State Drugs & Pharmaceuticals Ltd. Marck Biosciences Ltd. Mars Life Sciences Ltd. Martin & Harris Laboratories Ltd. Max India Ltd. Mayank & Lili Pharma Ltd. Mayo (India) Ltd. Mcneil & Argus Pharmaceuticals Ltd. Medicamen Biotech Ltd. Medispan Ltd. Medley Pharmaceuticals Ltd. Meghdoot Chemicals Ltd. Meher Pharma (India) Ltd. Merck Ltd. Mercury Laboratories Ltd. Mercury Phytochem Ltd. Merind Ltd. Mesco Pharmaceuticals Ltd. Metropolitan Overseas Ltd. Micro Labs Ltd. Monarch Laboratories Ltd. Morepen Laboratories Ltd. Mount Mettur Pharmaceuticals Ltd. N B Z Pharma Ltd. N R Jet Enterprises Ltd. Natco Pharma Ltd. Nem Organics Ltd. Neon Laboratories Ltd. Nestor Pharmaceuticals Ltd. Neulife Laboratories Ltd. Nirma Ltd. Nitya Laboratories Ltd. Novartis India Ltd. Novus Pharmaceuticals Ltd. Om Pharmaceuticals Ltd. Omega Biotech Ltd. Omega Laboratories Ltd. Onco Therapies Ltd. Opec Innovations Ltd. Orchid Chemicals & Pharmaceuticals Ltd. Organon (India) Ltd. Ozone Pharmaceuticals Ltd. P C I Chemicals & Pharmaceuticals Ltd. Paam Pharmaceuticals (Delhi) Ltd. Panacea Biotec Ltd. Parabolic Drugs Ltd. Paras Pharmaceuticals Ltd. Parke-Davis (India) Ltd. Penam Laboratories Ltd. Perk Pharmaceuticals Ltd. Pfimex Pharmaceuticals Ltd. Pfizer Ltd. Phaarmasia Ltd. Phar-East Laboratories Ltd. Pharmacia Healthcare Ltd. Pharmaids Pharmaceuticals Ltd. Pharmax Corporation Ltd. Pharmed Ltd. Phyto Specialities Pvt. Ltd. Plethico Pharmaceuticals Ltd. Procter & Gamble Hygiene & Health Care Ltd. Quality Pharmaceuticals Ltd. R P G Life Sciences Ltd. Rajasthan Drugs & Pharmaceuticals Ltd. Rajat Pharmachem Ltd. Ranbaxy Drugs Ltd. Ranbaxy Laboratories Ltd. Raptakos, Brett & Co. Ltd. Ravish Infusions Ltd. Reckitt Benckiser (India) Ltd. Rekvina Laboratories Ltd. Resonance Specialties Ltd. Rhone-Poulenc (India) Ltd. Rolex Pharmaceuticals Ltd. Rosemount Pharma India Ltd. Rubra Medicaments Ltd. Rupal Chemical Inds. Ltd. Rusan Pharma Ltd. S A M Biotech Ltd. Saket Projects Ltd. Sandoz (India) Ltd. [Amalgamated] Sanjeevanee Pharmaceuticals Ltd. Sanjivani Paranteral Ltd. Sanofi-Synthelabo (India) Ltd. Sarabhai Piramal Pharmaceuticals Pvt. Ltd. Sarala Pharmaceuticals Ltd. Sarthi Pharmaceuticals Ltd. Sarvodaya Labs Ltd. Schering-Plough (India) Pvt. Ltd. Senbo Industries Ltd. Shalina Laboratories Pvt. Ltd. Sharvani Pharmaceuticals Ltd. Shiv Herbal Research Laboratory Ltd. Sidmak Laboratories (India) Pvt. Ltd. Sigma Laboratories Ltd. Smith Stanistreet Pharmaceuticals Ltd. Smithkline Beecham Pharmaceuticals (India) Ltd. [Amalgamated] Solumiks Herbaceuticals Ltd. Sri Chakra Remedies Ltd. Sri Krishna Drugs Ltd. Sri Krishna Pharmaceuticals Ltd. Strides Arcolab Ltd. Sun Pharmaceutical Inds. Ltd. Surya Pharmaceutical Ltd. Sustime Pharma Ltd. Suyog Pharmaceuticals Pvt. Ltd. Swega Laboratories Ltd. Swet-Chem Antibiotics Ltd. Syncom Formulations (India) Ltd. Syncom Healthcare Ltd. T K Healthcare Ltd. Tablets (India) Ltd. Tamilnadu Dadha Pharmaceuticals Ltd. Targof Pure Drugs Ltd. Taulis Pharma Ltd. Teem Laboratories Ltd. Themis Medicare Ltd. Tonira Pharma Ltd. Torrent Pharmaceuticals Ltd. Toshvin Industries Ltd. Trans Medicare Ltd. Travel Co. In Pvt. Ltd. Troika Pharmaceuticals Ltd. Twilight Litaka Pharma Ltd. U S V Ltd. Uni-Sankyo Ltd. Uni-Ucb Ltd. Unibios Laboratories Ltd. Unichem Laboratories Ltd. Unicorn Pharmaceuticals (India) Ltd. Unimark Remedies Ltd. Unimed Investments Ltd. Unimed Technologies Ltd. Unique Pharmaceutical Laboratories Ltd. Universal Generics Ltd. Universal Pharmaceuticals Ltd. Unjha Formulations Ltd. Vellanova Pharmaceuticals Ltd. Venkat Pharma Ltd. Veronica Laboratories Ltd. Vista Pharmaceuticals Ltd. Vita Biopharma Pvt. Ltd. Vysali Pharmaceuticals Ltd. Wallace Pharmaceuticals Ltd. Wander Pvt. Ltd. Warren Pharmaceuticals Ltd. Welcure Drugs & Pharmaceuticals Ltd. White Way Products (Pharma) Ltd. Win-Medicare Pvt. Ltd. Wintac Ltd. Wockhardt’s Ltd. Wyeth Laboratories Ltd. Wyeth Ltd. Yogi Healthcare Ltd. Zenith Health Care Ltd. Zenotech Laboratories Ltd. Zillion Pharmachem Ltd. Zim Laboratories Ltd. Zuventus Healthcare Ltd. Zydus Animal Health Ltd. Zydus Pathline Ltd.
Plant capacity: 117 Lakhs Nos. /annumPlant & machinery: Rs. 125 Lakhs
Working capital: -T.C.I: Cost of Project: Rs. 1339 Lakhs
Return: 43.00%Break even: 54.00%
Add to Inquiry Add to Inquiry Basket

Saline and Dextrose Fluid (IV Fluid) BFS Technology

As part of the millennium development goals (MDGs), governments in the region have developed strategies directed at reducing the negative impact of diseases like HIV, Malaria or Tuberculosis on the society by 2015. The strategies include halting and reversing the spread of HIV/AIDS, reducing the level of malaria infection, and reducing prevalence and death rates associated with tuberculosis. Severe malaria results into high fever, which requires the use of Intravenous Fluids as the first line of treatment. However, due to limited local production and supply, the fluids are comparatively expensive compared to other developed world where they are affordable and readily available. In India, local monopolies and distributors that sell the fluids very costly import 98% of the IV Fluids. Faced with the current factual situation Govt. Oriented organization planned to establish Intravenous Project to locally produce and supply this very essential product to the healthcare sector as a noble contribution in improving healthcare services. The project expects to promote the common good in the Eastern Region, to reduce the current high level of deaths from 9-14% of in-patient visits in hospitals and health facilities. In medicine, saline (also saline solution) is a general phrase referring to a sterile solution of sodium chloride (NaCl, more commonly known as salt) in water, but is only sterile when it is to be placed parenterally (such as intravenously); otherwise, a saline solution is a salt water solution. The sterile solution is typically used for intravenous infusion, rinsing contact lenses, nasal irrigation, and often used to clean a new piercing. It is also a good medium to store an avulsed ("knocked out") tooth until it can be re-implanted by a dentist. Saline solutions are available in various formulations for different purposes. Salines are also used in cell biology, molecular biology, and biochemistry experiments. Uses & Applications There are four main ranges of application of highly specialized intravenous infusion solutions: • Treatment of discarded water and electrolyte metabolism, especially in severe cases. • Therapy of acid base in balances. • The volume substitution and volume replacement in surgery of accident victim suffering blood lose. • Paratrial nutrition for severally ill and post-operative patients. • Aqueous isotonic injection (5%) of dextrose is given as intravenous injections to increase the column of circulating blood in the shocks and hemorrhages and to counteract dehydration. Dextrose solution is used during post operative period when sodium extraction is reduced. • Dextrose solution with concentration of 10-15% is used as diuretic for increase in urine flow. • Dextrose solution of 5% normal salmic is used for restarting fluid volume in circulation of an emergency as in accidents. • Saline solution is used when large amount of sodium has been lost by vomiting or by gastric or intestinal duodenal aspiration or through analimucation fistuala. • Dextrose monohydrate is used as supplement to cow's milk in part of feeding. • Hypertonic dextrose solution (25-50%) is in medical treatment partly because they are believed to strengthen heart muscles. • Hypertonic solutions are used in intravenous injection to relieve intractable pressure in patient with hydrocephalus and meningitis. Market Survey Our system of medicine like Ayurveda were well established and schools and hospitals with treatises and instruction manuals were in wide use. The growth of I.V. fluid manufacturing was faster than the growth rate of drugs. I.V fluids are the solutions applied directly to the vein of a patient who suffer from the weaknesses due to the deficiency of body fluids. These IV fluids are the best alternative which can yield sudden result in the health of a patient by replenishing the body fluids. Liquid glucose and dextrose are being produced in the organized sector. Glucose is produced in solid as well as in liquid form and dextrose is in anhydrous and monohydrous form. The gap between the production and consumption of liquid glucose is removed by the import. I.V. fluid demand is normally linked to the number of hospital beds. Observations show that 18 bottles of I.V. fluids are consumed per bed per month in the country. The demand is estimated to increase at a rate of 9 to 12% per annum. The present demand level is estimated to be around 2200 lakh bottles per annum. Areas with high population density and average temperatures are major consumption areas of I.V. fluids. Demand is high Uttar Pradesh, Rajasthan, Haryana, Bihar, Madhya Pradesh and West Bengal. North India alone account for one third of the total demand in the country.
Plant capacity: 48000 Bottles/day(500 ml)Plant & machinery: 253 Lakhs
Working capital: -T.C.I: Cost of Project: 834 Lakhs
Return: 29.00%Break even: 52.00%
Add to Inquiry Add to Inquiry Basket

I.V. FLUID - Manufacturing Plant, Detailed Project Report, Profile, Business Plan, Industry Trends, Market Research, Survey, Manufacturing Process, Machinery, Raw Materials, Feasibility Study, Investment Opportunities, Cost and Revenue, Plant Economics

Intravenous fluids are fluids which are intended to be administered to a patient intravenously, directly through the circulatory system. These fluids must be sterile to protect patients from injury, and there are a number of different types available for use. Fluids are given when someone's body fluid volume falls. There are a number of things which can cause a drop in fluid volume. Vomiting and diarrhea are a classic example, which is why people are encouraged to drink fluids when they are sick, to keep their fluid volume stable. Another cause is blood loss, which causes problems both because people lose blood products, and because they experience a loss in fluid volume. Electrolyte levels in the blood can also become unstable as a result of rapid changes in fluid volume, in which case intravenous fluids can be used to restore the balance. Intravenous fluids can be broken into two broad groups. Crystalloids such as saline solutions contain a solution of molecules which can dissolve in water. When crystalloids are administered, they tend to create low osmotic pressure, allowing fluid to move across the blood vessels, and this can be linked with edema. Colloids contain particles which are not soluble in water, and they create high osmotic pressure, attracting fluid into the blood vessels. Blood is an example of a commonly administered intravenous colloid. Intravenous fluids can also be used as a route of medication administration. If a doctor wants to deliver a small amount of medication over an extended period of time, it can be dissolved in a bag of intravenous fluids and set on an infusion pump which delivers the medicated fluid directly into the blood. They are also commonly used to assist with surgical recovery; people who receive fluids after surgery tend to experience better recovery than people who do not. There are many solutions are used for IV fluids. The specific one used depends on the situation. Many other compounds can be added to the IV solution as a simple means of administration. For example, antibiotics, pain killers and so on can be added to the IV so the patient receives the drug at a constant rate over a long period of time. The basic function of IV fluids is to replenish the body fluids. Although there are a number of IV fluids but generally three types of IV fluids are used in hospitals as IV drips. They are as follows: 1. Dextrose injection fluid 2. Dextrose and sodium chloride injection fluid 3. Sodium chloride injection solution (Saline solution). When saline is injected intravenously, it compensate the deficiency of sodium ions when dextrose is injected it gives energy due to glucose content of it when dextro-saline is given in combination, it replenishes the dehydration as well as gives energy thereby recouping debility syndrome and also in general take care of malaise. Uses There are four main ranges of application of highly specialized intravenous infusion solutions: 1. Treatment of discarded water and electrolyte metabolism, especially in severe cases. 2. Therapy of acid base in balances. 3. The volume substitution and volume replacement in surgery of accident victim suffering blood loss. 4. Paratral nutrition for severally ill and post-operative patients. 5. Aqueous isotonic injection (5%) of dextrose is given as intravenous injections to increase the column of circulating blood in the shocks and haemarrhages and to counteract dehydration. When it is desired to replace excessive salt loss also glucose is injected along with sodium chloride. 6. Dextrose solution is used during postoperative period when sodium extraction is reduced. 7. Dextrose solution with concentration of 10-15% is used as diuretic for increase in urine flow. 8. Dextrose solutions of 5% normal salinic are used for restoring fluid volume in circulation of an emergency as in accidents with haemarrhage. Saline solution is used when large amount of sodium has been lost by vomiting or by gastric or intestinal duodenal aspiration or through an alimentary fistula. 9. Dextrose monohydrate is used as supplement to cow's milk in part of feeding. 10. Hypertonic dextrose solution (25-50%) is in medical treatment partly because they are believed to strengthen heart muscles. Hypertonic solutions are used in intravenous injection to relieve intractable pressure in-patient with hydrocephalus and meningitis. Market Survey India's traditions in the science of health and healing go back to the halcyon days of Surushta, Vagbhatta and Charaka. Our system of medicine like Ayurveda were well established and schools and hospitals with treatises and instruction manuals were in wide use. The establishment of modern pharmaceutical industry in India may be said to have commercial with the selling up of Bengal chemicals by acharya P.C Ray in Kolkata and of Alembic Chemical in B.D Amin. The growth of I.V. fluid manufacturing was faster than the growth rate of drugs. I.V fluids are the solutions applied directly to the vein of a patient who suffer from the weaknesses due to the deficiency of body fluids. These IV fluids are the best alternative which can yield sudden result in the health of a patient by replanishing the body fluids. Liquid glucose and dextrose are being produced in the organized sector. Glucose is produced in solid as well as in liquid form and dextrose is in anhydrous and monohydros form. The installed capacity, production and capacity utilization of liquid glucose are indicated below. I.V. fluid demand is normally linked to the number of hospital beds. Observations show that 18 bottles of I.V. fluids are consumed per bed per month in the country. The demand is estimated to increase at a rate of 9 to 12% per annum. The present demand level is estimated to be around 2200 Lakh bottles per annum. Areas with high population density and average temperatures are major consumption areas of I.V. fluids. Demand is high Uttar Pradesh, Rajasthan, Haryana, Bihar, Madhya Pradesh and West Bengal. North India alone account for one third of the total demand in the country. Few Indian Major Players are as under Ahlcon Parenterals (India) Ltd. Core Laboratories Ltd. Gujarat Ambuja Proteins Ltd. Gujarat Inject Ltd. Haffkine Bio-Pharmaceutical Corpn. Ltd. India Infusion Ltd. Indian Maize & Chemicals Ltd. K G Gluco Biols Ltd. Kamala Sugar Mills Ltd. Kokad Pharmaceutical Laboratories Ltd. Marck Biosciences Ltd. Origin Agrostar Ltd. Parenteral Surgicals Ltd. Senbo Industries Ltd. Span Medicals Ltd. Tirupati Starch & Chemicals Ltd. Unique Sugars Ltd. Wockhardt Health Care Ltd.
Plant capacity: 144,00,000 Bottles/AnnumPlant & machinery: Rs. 808 Lakhs
Working capital: -T.C.I: Cost of Project: Rs 1367 Lakhs
Return: 26.00%Break even: 46.00%
Add to Inquiry Add to Inquiry Basket

Disposable Plastic Syringes - Manufacturing Plant, Detailed Project Report, Profile, Business Plan, Industry Trends, Market Research, Survey, Manufacturing Process, Machinery, Raw Materials, Feasibility Study, Investment Opportunities, Cost and Revenue

It is an instrument which is used for injecting any liquid into the body of human beings or of animals. These syringes are used for injecting the medicine into the body or into the nerve of the body which are not possible to take in through mouth or takes much time in mixing with blood. A syringe is a simple piston pump consisting of a plunger that fits tightly in a tube. The plunger can be pulled and pushed along inside a cylindrical tube (the barrel), allowing the syringe to take in and expel a liquid or gas through an orifice at the open end of the tube. The open end of the syringe may be fitted with a hypodermic needle, a nozzle, or tubing to help direct the flow into and out of the barrel. The constantly increasing use of Disposable Syringes made of plastic Material indicates its importance, which is based mainly on the advantages it offers regarding cost and hygienic applications. Due to their availability is sterilized condition, ready to use and cost effectiveness, disposable syringes are fast replacing the age-old glass syringes. Disposable syringes are mostly injection moulded from polypropylene. Syringes are available in sizes of 1ml, 2ml, and 10ml, in a variety of designs and consist of either two or three components in their material of construction. The number and size of injection moulding machines required depends upon syringe construction, number of mould cavities and annual production. Uses & Applications Disposable syringes commonly are used in modern medicine for the injection of drugs and vaccines or for the extraction of blood. Among the common uses of disposable syringes are the injecting of insulin by a diabetic person and the administering of a local anesthesia by a dentist. Disposable syringes are favored over reusable syringes for vaccines, in order to avoid the risk of transmitting blood-borne diseases such as human immunodeficiency virus (HIV) and hepatitis from one person to another. Disposable syringes also are used to inject anesthetics for medical procedures. They can be used either alone or in combination with anesthetic gas for general anesthesia. They can be used in combination with anesthetic spray or cream for local anesthesia. The syringes used by dentists to administer local anesthesia before drilling or pulling teeth are a common example. Disposable syringes sometimes are used for drawing blood samples. They allow greater precision than evacuated tube systems, so syringes used together with butterfly needles often are favored when drawing blood. Market Survey The Indian healthcare sector, including pharmaceutical, diagnostics and hospital services, is expected to more than double its revenues to Rs 2500 bn by 2014. Expenditure on healthcare services, including diagnostics, hospital occupancy and outpatient consulting, the largest component of this spend is expected to grow more than 125% to Rs 1560 bn. The Indian domestic Medicare devices industry is expected to grow from Rs 60 bn to Rs 76.5 bn in four years. The overall market is estimated at Rs 150 bn. A major part of the demand is met through imports. Devices, such as catheters and stents represent nearly two-fifth of the entire range of diagnostic devices and most critical as per international classification. Presently medical devices are treated like drugs and regulated by state drug regulators under the drug law - Drugs and Cosmetics Act. Guidelines would make it mandatory for producers to get their products certified by notified bodies like ISO and BIS. The market for non-premium equipments, appliances and disposables is, however, dominated by the domestic manufacturers, while foreign suppliers and Indian companies with foreign alliances dominate the high-end hi-tech medical equipment and appliances. With the healthcare sector being opened up to private players, India is now emerging as a lucrative market for global firms dealing in hi-tech diagnostic and imaging equipment. In the Indian single uses syringes market, which is nearly 1.5 bn units strong, Hindustan Syringes and Medical Devices (HMD) enjoys a 65% market share. Imports constitute 10% of this market. In the single use needles market, HMD has a 70% market share, followed by imported brands with a 25% market share. The size of the local needles market is 2.5 bn units per annum. With the opening of healthcare sector, the market for medical equipment and accessories has become more vibrant. A large number of new medical facilities have been created by a large numbers of service providers, which is indicative of the great potential for medical equipment in India. The Indian market is expanding in all directions as a result of better affordability, greater health consciousness and expanding medical service institutions. With a population of 1.15 bn, India will need to at least 2 mn beds in the next 10 years in order to attain a modest target of 2 per 1000 of population. With a total healthcare value of USD 400 bn, the potential for Medicare equipment is, indeed large. Although there is a large untapped potential, the industry is confronted with problems of low volumes, high cost of production/operation, and rapid obsolescence as a result of accelerated, almost continuous, technological breakthroughs. The fragmentation of production facilities forestalls any worthwhile effort at R&D. This leads to industry's dependence on imported technology. Nonetheless, it is crystal clear that with the fast commercialization process of the sector and upgradation of medical facilities, the potential is sky-high. Few Major Players are listed below: Albert David Ltd. Disposable Medi-Aids Ltd. H L L Lifecare Ltd. Hindustan Syringes & Medical Devices Ltd. Iscon Surgicals Ltd. La Medical Devices Ltd. Lifeline Injects Ltd. Lifelong Meditech Ltd. Nirma Ltd. Raaj Medisafe India Ltd. Sangam Health Care Products Ltd. Surgiplast Ltd.
Plant capacity: 180 Lakh Nos. /annumPlant & machinery: 245 Lakhs
Working capital: -T.C.I: Cost of Project: 455 Lakhs
Return: 26.00%Break even: 46.00%
Add to Inquiry Add to Inquiry Basket

Saline and Dextrose Fluid (IV Fluid) BFS Technology

As part of the millennium development goals (MDGs), governments in the region have developed strategies directed at reducing the negative impact of diseases like HIV, Malaria or Tuberculosis on the society by 2015. The strategies include halting and reversing the spread of HIV/AIDS, reducing the level of malaria infection, and reducing prevalence and death rates associated with tuberculosis. Severe malaria results into high fever, which requires the use of Intravenous Fluids as the first line of treatment. However, due to limited local production and supply, the fluids are comparatively expensive compared to other developed world where they are affordable and readily available. In India, local monopolies and distributors that sell the fluids very costly import 98% of the IV Fluids. Faced with the current factual situation Govt. Oriented organization planned to establish Intravenous Project to locally produce and supply this very essential product to the healthcare sector as a noble contribution in improving healthcare services. The project expects to promote the common good in the Eastern Region, to reduce the current high level of deaths from 9-14% of in-patient visits in hospitals and health facilities. In medicine, saline (also saline solution) is a general phrase referring to a sterile solution of sodium chloride (NaCl, more commonly known as salt) in water, but is only sterile when it is to be placed parenterally (such as intravenously); otherwise, a saline solution is a salt water solution. The sterile solution is typically used for intravenous infusion, rinsing contact lenses, nasal irrigation, and often used to clean a new piercing. It is also a good medium to store an avulsed ("knocked out") tooth until it can be re-implanted by a dentist. Saline solutions are available in various formulations for different purposes. Salines are also used in cell biology, molecular biology, and biochemistry experiments. Uses & Applications There are four main ranges of application of highly specialized intravenous infusion solutions: • Treatment of discarded water and electrolyte metabolism, especially in severe cases. • Therapy of acid base in balances. • The volume substitution and volume replacement in surgery of accident victim suffering blood lose. • Paratrial nutrition for severally ill and post-operative patients. • Aqueous isotonic injection (5%) of dextrose is given as intravenous injections to increase the column of circulating blood in the shocks and hemorrhages and to counteract dehydration. Dextrose solution is used during post operative period when sodium extraction is reduced. • Dextrose solution with concentration of 10-15% is used as diuretic for increase in urine flow. • Dextrose solution of 5% normal salmic is used for restarting fluid volume in circulation of an emergency as in accidents. • Saline solution is used when large amount of sodium has been lost by vomiting or by gastric or intestinal duodenal aspiration or through analimucation fistuala. • Dextrose monohydrate is used as supplement to cow's milk in part of feeding. • Hypertonic dextrose solution (25-50%) is in medical treatment partly because they are believed to strengthen heart muscles. • Hypertonic solutions are used in intravenous injection to relieve intractable pressure in patient with hydrocephalus and meningitis. Market Survey Our system of medicine like Ayurveda were well established and schools and hospitals with treatises and instruction manuals were in wide use. The growth of I.V. fluid manufacturing was faster than the growth rate of drugs. I.V fluids are the solutions applied directly to the vein of a patient who suffer from the weaknesses due to the deficiency of body fluids. These IV fluids are the best alternative which can yield sudden result in the health of a patient by replenishing the body fluids. Liquid glucose and dextrose are being produced in the organized sector. Glucose is produced in solid as well as in liquid form and dextrose is in anhydrous and monohydrous form. The gap between the production and consumption of liquid glucose is removed by the import. I.V. fluid demand is normally linked to the number of hospital beds. Observations show that 18 bottles of I.V. fluids are consumed per bed per month in the country. The demand is estimated to increase at a rate of 9 to 12% per annum. The present demand level is estimated to be around 2200 lakh bottles per annum. Areas with high population density and average temperatures are major consumption areas of I.V. fluids. Demand is high Uttar Pradesh, Rajasthan, Haryana, Bihar, Madhya Pradesh and West Bengal. North India alone account for one third of the total demand in the country.
Plant capacity: 48000 Bottles/day(500 ml)Plant & machinery: 253 Lakhs
Working capital: -T.C.I: Cost of Project: 834 Lakhs
Return: 29.00%Break even: 52.00%
Add to Inquiry Add to Inquiry Basket

I.V. Fluid - Manufacturing Plant, Detailed Project Report, Profile, Business Plan, Industry Trends, Market Research, Survey, Manufacturing Process, Machinery, Raw Materials, Feasibility Study, Investment Opportunities, Cost and Revenue, Plant Economics

Intravenous fluids are fluids which are intended to be administered to a patient intravenously, directly through the circulatory system. Fluids are given when someone's body fluid volume falls. Liquid glucose and dextrose are being produced in the organized sector. I.V. fluid demand is normally linked to the number of hospital beds. Observations show that 18 bottles of I.V. fluids are consumed per bed per month in the country. The demand is estimated to increase at a rate of 9 to 12% per annum. The present demand level is estimated to be around 2200 Lakh bottles per annum. Areas with high population density and average temperatures are major consumption areas of I.V. fluids. Demand is high Uttar Pradesh, Rajasthan, Haryana, Bihar, Madhya Pradesh and West Bengal. North India alone account for one third of the total demand in the country. Few Indian Major Players are as under Ahlcon Parenterals (India) Ltd. Core Laboratories Ltd. Gujarat Ambuja Proteins Ltd. Gujarat Inject Ltd. Haffkine Bio-Pharmaceutical Corpn. Ltd. India Infusion Ltd. Indian Maize & Chemicals Ltd. K G Gluco Biols Ltd. Kamala Sugar Mills Ltd. Kokad Pharmaceutical Laboratories Ltd. Marck Biosciences Ltd. Origin Agrostar Ltd. Parenteral Surgicals Ltd. Senbo Industries Ltd. Span Medicals Ltd. Tirupati Starch & Chemicals Ltd. Unique Sugars Ltd. Wockhardt Health Care Ltd.
Plant capacity: 144,00,000 Bottles/AnnumPlant & machinery: Rs. 808 Lakhs
Working capital: -T.C.I: Cost of Project: Rs 1367 Lakhs
Return: 26.00%Break even: 46.00%
Add to Inquiry Add to Inquiry Basket

Disposable Plastic Syringes - Manufacturing Plant, Detailed Project Report, Profile, Business Plan, Industry Trends, Market Research, Survey, Manufacturing Process, Machinery, Raw Materials, Feasibility Study, Investment Opportunities, Cost and Revenue

It is an instrument which is used for injecting any liquid into the body of human beings or of animals. The Indian healthcare sector, including pharmaceutical, diagnostics and hospital services, is expected to more than double its revenues to Rs 2500 bn by 2014. The Indian domestic Medicare devices industry is expected to grow from Rs 60 bn to Rs 76.5 bn in four years. The overall market is estimated at Rs 150 bn. A major part of the demand is met through imports. With the healthcare sector being opened up to private players, India is now emerging as a lucrative market for global firms dealing in hi-tech diagnostic and imaging equipment. In the Indian single uses syringes market, which is nearly 1.5 bn units strong, Hindustan Syringes and Medical Devices (HMD) enjoys a 65% market share. Imports constitute 10% of this market. In the single use needles market, HMD has a 70% market share, followed by imported brands with a 25% market share. The size of the local needles market is 2.5 bn units per annum. It is crystal clear that with the fast commercialization process of the sector and upgradation of medical facilities, the potential is sky-high. Few Major Players are listed below: Albert David Ltd. Disposable Medi-Aids Ltd. H L L Lifecare Ltd. Hindustan Syringes & Medical Devices Ltd. Iscon Surgicals Ltd. La Medical Devices Ltd. Lifeline Injects Ltd. Lifelong Meditech Ltd. Nirma Ltd. Raaj Medisafe India Ltd. Sangam Health Care Products Ltd. Surgiplast Ltd.
Plant capacity: 180 Lakh Nos. /annumPlant & machinery: Rs.245 Lakhs
Working capital: -T.C.I: Cost of Project:Rs. 455 Lakhs
Return: 26.00%Break even: 46.00%
Add to Inquiry Add to Inquiry Basket

Information
  • One Lac / Lakh / Lakhs is equivalent to one hundred thousand (100,000)
  • One Crore is equivalent to ten million (10,000,000)
  • T.C.I is Total Capital Investment
  • We can modify the project capacity and project cost as per your requirement.
  • We can also prepare project report on any subject as per your requirement.
  • Caution: The project's cost, capacity and return are subject to change without any notice. Future projects may have different values of project cost, capacity or return.

Add multiple items to inquiry
Select the items and then press Add to inquiry button

Page 12 of 21 | Total 201 projects in this category
« Previous   Page 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 .... 20 21   Next »

About NIIR PROJECT CONSULTANCY SERVICES

Hide »

NIIR PROJECT CONSULTANCY SERVICES (NPCS) is a reliable name in the industrial world for offering integrated technical consultancy services. NPCS is manned by engineers, planners, specialists, financial experts, economic analysts and design specialists with extensive experience in the related industries.

Our various services are: Detailed Project Report, Business Plan for Manufacturing Plant, Start-up Ideas, Business Ideas for Entrepreneurs, Start up Business Opportunities, entrepreneurship projects, Successful Business Plan, Industry Trends, Market Research, Manufacturing Process, Machinery, Raw Materials, project report, Cost and Revenue, Pre-feasibility study for Profitable Manufacturing Business, Project Identification, Project Feasibility and Market Study, Identification of Profitable Industrial Project Opportunities, Business Opportunities, Investment Opportunities for Most Profitable Business in India, Manufacturing Business Ideas, Preparation of Project Profile, Pre-Investment and Pre-Feasibility Study, Market Research Study, Preparation of Techno-Economic Feasibility Report, Identification and Section of Plant, Process, Equipment, General Guidance, Startup Help, Technical and Commercial Counseling for setting up new industrial project and Most Profitable Small Scale Business.

NPCS also publishes varies process technology, technical, reference, self employment and startup books, directory, business and industry database, bankable detailed project report, market research report on various industries, small scale industry and profit making business. Besides being used by manufacturers, industrialists and entrepreneurs, our publications are also used by professionals including project engineers, information services bureau, consultants and project consultancy firms as one of the input in their research.

^ Top